Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of NOX66 in Healthy Subjects
NCT03780465Phase 1Withdrawn
- Sponsor
- Noxopharm Limited
- Start
- Mar 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of idronoxil in solid tumor (3 arms), sponsored by Noxopharm Limited. Primary endpoints: Area Under the concentration-time Curve, Maximal observed concentration and 3 more. Planned start Mar 2019; status: withdrawn.
02
Drugs
idronoxil
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03780465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03780465.